ClinicalTrials.gg
CompletedNCT07938554Updated Nov 16, 2026

Effect of Erythritol Air Polishing on Inflammatory Cytokines in Peri-implantitis

An interventional study of air-polishing devices and non-surgical treatment in Peri-implantitis, sponsored by Ordu University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Ordu University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Sep 2025, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Peri-Implantitis with a site in Turkey — 15 open to participants now, 18 under way, none of them phase 3. Peri-Implantitis · Turkey.

Enrollment
11th of 26
54 · median 50
Started
2025
with 7 others
No phase
26 of 54
10 open now
Registered
54th of 54
by date

Among the 54 studies in Peri-Implantitis with a site in Turkey, this one is the 11th largest by enrollment of the 26 interventional ones that give a count, is one of 8 that started in 2025, is one of 26 with no phase, and was the 54th registered.

Peri-Implantitis

323 studies on the registry are indexed under Peri-Implantitis; 88 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

15 of the 54 studies in Peri-Implantitis with a site in Turkey are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 49 Peri-Implantitis studies recruiting now, 27 (55%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Peri-Implantitis with a site in Turkey, or all of them as a file.
02

Study summary

This study aimed to assess the effect of subgingival air polishing with erythritol as an adjunctive treatment in the non-surgical treatment of peri-implantitis on clinical parameters and inflammatory cytokine levels (IL-1β, TNF-α, IL-8, and IL-36) peri-implant crevicular fluid (PICF) among patients with peri-implantitis.

Read the detailed description

The aim of this study was to evaluate the effects of adjunctive use of air-polishing devices (APDs) to non-surgical treatment (NST) on clinical parameters and the levels of IL-1β, TNF-α, IL-8, and IL-36 in peri-implant crevicular fluid (PICF) of patients with peri-implantitis. Fifty-four participants (54 implants) with functional implants (≥1 year) were included in a randomized, parallel group clinical trial. The control group consisted of 19 individuals with healthy implants, while the test group comprised 35 patients with peri-implantitis; 18 patients were randomly assigned to receive treatment with APDs (Airflow Master Piezon®, EMS) +NST, and another 17 patients were treated with NST using only titanium curettes. Clinical parameters (plaque index, gingival index, bleeding on probing, probing pocket depth, radiographic bone level, suppuration, and keratinized mucosa width) were recorded after PICF sampling. Data was collected once for controls, and at baseline and 3 months post-treatment for test groups. Biomarker levels were analyzed using ELISA.

03

Conditions studied

  • Peri-implantitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Having been using implant-supported fixed prostheses for more than 1 year. Radiographically, eligible implants were required to present a bone loss of ≥3 mm, accompanied by a clinical probing pocket depth (PPD) of 6-9 mm for peri-implantitis patients.

Exclusion criteria

Exclusion Criteria:

The exclusion criteria were defined as follows: the presence of any systemic disease, particularly uncontrolled diabetes, uncontrolled hypertension, or severe cardiac conditions; current pregnancy or lactation; history of smoking or use of other tobacco products; and systemic conditions or long-term medication use known to affect bone metabolism, such as , bisphosphonates, or a history of radiotherapy. Additionally, individuals who had received antibiotic or antimicrobial therapy for any reason within the preceding 6 months, those who had undergone prior periodontal or peri-implant therapy before the commencement of the study, and individuals under 18 years of age or unwilling to provide were excluded from the study. In addition, mobil implants, implants previously subjected to surgical treatment for peri-implantitis, and implants for which reliable probing measurements could not be obtained were excluded from the analysis.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
54 participants (actual)

Study arms

  • Active comparator
    Test Group

    Air-polishing devices (APDs) + non-surgical treatment (NST)

    Device: air-polishing devices

  • Active comparator
    Test group

    Only non-surgical treatment (NST)

    Other: non-surgical treatment

  • Other
    Control group

    healthy implants

    Other: healthy implant

Interventions

  • Deviceair-polishing devices

    Subgingival air polishing performed using erythritol powder with an air-polishing device

    Also known as: Airflow Master Piezon®, EMS

  • Othernon-surgical treatment

    only non-surgical treatment

  • Otherhealthy implant

    Individuals with peri-implant and periodontal health and clinically healthy implants

06

What researchers measure

Primary outcomes

  1. Plaque Index

    to assess plaque accumulation

    Time frame: Baseline

  2. Plaque Index

    to assess plaque accumulation

    Time frame: 3 months post-treatment

  3. Gingival Index

    for evaluating gingival inflammation

    Time frame: Baseline

  4. Gingival Index

    for evaluating gingival inflammation

    Time frame: 3 months post-treatment

  5. Probing pocket depth

    for measuring disease severity

    Time frame: Baseline

  6. Probing pocket depth

    for measuring disease severity

    Time frame: 3 months post-treatment

  7. Bleeding on Probing

    to assess disease activity

    Time frame: Baseline

  8. Bleeding on Probing

    to assess disease activity

    Time frame: 3 months post-treatment

  9. Radiographic Bone Level

    RBL was determined by measuring, in millimeters, the distance between the implant neck/reference point and the marginal bone level at the mesial and distal aspects of each implant. The mean of the mesial and distal measurements was calculated to obtain the overall RBL value for each implant

    Time frame: Baseline

  10. Radiographic Bone Level

    RBL was determined by measuring, in millimeters, the distance between the implant neck/reference point and the marginal bone level at the mesial and distal aspects of each implant. The mean of the mesial and distal measurements was calculated to obtain the overall RBL value for each implant

    Time frame: 3 months post-treatment

  11. Suppuration on Probing

    Suppuration on Probing (SoP) to determine the presence or absence of purulent discharge from the peri-implant sulcus

    Time frame: Baseline

  12. Suppuration on Probing

    Suppuration on Probing (SoP) to determine the presence or absence of purulent discharge from the peri-implant sulcus

    Time frame: 3 months post-treatment

  13. Keratinized Mucosa Width

    Keratinized Mucosa Width (KMW) to assess the width of the keratinized mucosa around the implants

    Time frame: Baseline

  14. Keratinized Mucosa Width

    Keratinized Mucosa Width (KMW) to assess the width of the keratinized mucosa around the implants

    Time frame: 3 months post-treatment

  15. IL-1β

    IL-1β levels in peri-implant crevicular fluid (PICF)

    Time frame: Baseline

  16. IL-1β

    IL-1β levels in peri-implant crevicular fluid (PICF)

    Time frame: 3 months post-treatment

  17. TNF-α

    TNF-α levels in peri-implant crevicular fluid (PICF)

    Time frame: Baseline

  18. TNF-α

    TNF-α levels in peri-implant crevicular fluid (PICF)

    Time frame: 3 months post-treatment

  19. IL-8

    IL-8 levels in peri-implant crevicular fluid (PICF)

    Time frame: Baseline

  20. IL-8

    IL-8 levels in peri-implant crevicular fluid (PICF)

    Time frame: 3 months post-treatment

  21. IL-36

    IL-36 levels in peri-implant crevicular fluid (PICF)

    Time frame: Baseline

  22. IL-36

    IL-36 levels in peri-implant crevicular fluid (PICF)

    Time frame: 3 months post-treatment

07

Study locations

1 site
  • Figen Öngöz Dede
    Ordu, Altinordu 52100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Dec 2025, 3 months.

Of 121 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's 3 months is below that.

Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Sep 1, 2025
Primary completionActual
Dec 5, 2025
CompletionActual
Feb 5, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938554
Lead sponsor
Ordu University
Responsible party
Prof.Dr. Figen ÖNGÖZ DEDE (Clinical Professor, Ordu University) — Principal investigator
First posted
Nov 16, 2026
Start date
Sep 1, 2025
Primary completion
Dec 5, 2025
Completion
Feb 5, 2026
Last update
Nov 16, 2026

Study contacts

Figen ÖNGÖZ DEDE
principal investigator · Ordu University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion